268 related articles for article (PubMed ID: 29269513)
1. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN; Raftis J; Wilson SJ; Perera V; Garonzik SM; Murthy B; Everlof JG; Aronson R; Luettgen J; Newby DE
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2678-2685. PubMed ID: 32907366
[TBL] [Abstract][Full Text] [Related]
3. PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies.
Nash J; Meah MN; Whittington B; Debono S; Raftis J; Miller MR; Sorbie A; Mills NL; Nespoux J; Bruce L; Duffin R; Dhaun N; Brittan M; Chao L; Merali S; Kim M; Wang Z; Zhang Y; Jin S; Wang B; Kozinn M; Newby DE
Arterioscler Thromb Vasc Biol; 2024 Apr; 44(4):987-996. PubMed ID: 38357820
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
5. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
[TBL] [Abstract][Full Text] [Related]
7. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.
Wilson SJ; Connolly TM; Peters G; Ghosh A; Johnson M; Newby DE
Cardiovasc Res; 2019 Mar; 115(3):669-677. PubMed ID: 30184110
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
[TBL] [Abstract][Full Text] [Related]
9. New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans.
Merali S; Wang Z; Frost C; Callejo M; Hedrick M; Hui L; Meadows Shropshire S; Xu K; Bouvier M; DeSouza MM; Yang J
Platelets; 2022 Oct; 33(7):969-978. PubMed ID: 35758258
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
11. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES; Banville J; Deon D; Dubé L; Gagnon M; Guy J; Lapointe P; Lavallée JF; Martel A; Plamondon S; Rémillard R; Ruediger E; Tremblay F; Posy SL; Guarino VR; Richter JM; Li J; Gupta A; Vetrichelvan M; Balapragalathan TJ; Mathur A; Hua J; Callejo M; Guay J; Sum CS; Cvijic ME; Watson C; Wong P; Yang J; Bouvier M; Gordon DA; Wexler RR; Marinier A
J Med Chem; 2022 Jul; 65(13):8843-8854. PubMed ID: 35729784
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of BMS-986120 and its deuterated derivatives as PAR4 antagonists.
Chen P; Ren S; Song H; Chen C; Chen F; Xu Q; Kong Y; Sun H
Bioorg Med Chem; 2019 Jan; 27(1):116-124. PubMed ID: 30503410
[TBL] [Abstract][Full Text] [Related]
14. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study.
Balasubramaniam K; Viswanathan G; Dragone J; Grose-Hodge R; Martin P; Troy S; Preston P; Zaman AG
Thromb Haemost; 2014 Jul; 112(1):205-15. PubMed ID: 24553755
[TBL] [Abstract][Full Text] [Related]
18. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
[TBL] [Abstract][Full Text] [Related]
20. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
